COVID19

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.

Arc Capital Partners and Belay Investment Group Successfully Exit Their Investment in Lido Marina Village

Retrieved on: 
Thursday, February 29, 2024
Commercial Building & Real Estate, Urban Planning, Construction & Property, REIT, Restaurant, DJM, Investment, Aesop, Entrepreneurship, COVID-19, JLL, COVID19, CIO, Partnership

Arc Capital Partners (Arc) and Belay Investment Group (Belay) announced today that they have successfully exited their preferred equity investment in Lido Marina Village (Lido), a 100% leased, 106,000-square-foot mixed-use property located in Newport Beach, CA.

Key Points: 
  • Arc Capital Partners (Arc) and Belay Investment Group (Belay) announced today that they have successfully exited their preferred equity investment in Lido Marina Village (Lido), a 100% leased, 106,000-square-foot mixed-use property located in Newport Beach, CA.
  • The transaction validated the significant value created by DJM Capital Partners (DJM), which has owned and operated the property since 2013.
  • Arc, through its partnership with Belay, provided capital for DJM to complete a recapitalization of the construction loan during the COVID19 pandemic.
  • “DJM was excited to partner with Arc through a turbulent time in the capital markets,” said Lindsay Parton, DJM’s President.

Docubee Shines in 2023, Setting the Standard with Gartner Recognition

Retrieved on: 
Thursday, March 7, 2024
Software, Accusoft, IPad, HR, Communication, COVID19

TAMPA, Fla., March 7, 2024 /PRNewswire/ -- Docubee, an Accusoft brand and a leading intelligent contract automation platform, proudly announces its outstanding performance in 2023, receiving multiple badges from Gartner Digital Markets highlighting the software's excellence in various categories.

Key Points: 
  • User reviews on Capterra emphasize Docubee's impact:
    Lori H. notes, "Customer service is very good.
  • This recognition highlights Docubee's commitment to providing exceptional customer support, ensuring a seamless user experience.
  • "We are thrilled to receive this recognition from Gartner, affirming Docubee's commitment to delivering unparalleled value and user-friendly experiences in the intelligent contract space.
  • Docubee has consistently maintained its status as a top-rated product on all Gartner Digital Markets sites, with an overall rating of 4.8 out of 5.

CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

Retrieved on: 
Monday, January 22, 2024
COVAXIN, World Health Organization, Texas Children's Hospital, UNICEF, COVID19, Tropical medicine, Dean (education), EUL, Medicine, DRS, CVD, BCM, National academy, Baylor College of Medicine, UN, RBD, Baylor University, GMP, Good, CDSCO, Dean, WHO, Safety, COVID-19, Hospital, Biomedical Research, Good manufacturing practice, Nobel Peace Prize, Alum, Vaccine, DCGI, SARS-CoV-2, National school, Biology

HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),

Key Points: 
  • "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
  • By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
  • Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
  • The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Study in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 14, 2023
Safety, Interim, ASH, Cohort, Headache, PD, PNH, Patient, ULN, IgA nephropathy, Week, Microangiopathy, Pharmacokinetics, Immunoglobulin A, COVID19, Common, Society, RBC, LDH, Medical device, Pharmaceutical industry, Fine chemical, Vaccine

The interim results support the advancement of KP104 to Phase 3 studies as an optimal and safe treatment for PNH patients to address currently unmet medical needs.

Key Points: 
  • The interim results support the advancement of KP104 to Phase 3 studies as an optimal and safe treatment for PNH patients to address currently unmet medical needs.
  • The presentation has also been selected to be featured in the 2024 Highlights of ASH.
  • Kira Pharmaceuticals is committed to advancing KP104 as an innovative therapy for patients with PNH and other complement-mediated diseases.
  • Title: KP104, a bifunctional C5 antibody/factor H fusion protein, effectively controls both intravascular and extravascular hemolysis: interim results from a phase 2 study in complement inhibitor-naïve PNH patients

Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis Report 2023-2029: Focus on Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 4, 2023
Health, Pharmaceutical, Infusion, System, Fresenius (company), IV, Pump, Injury, Ageing, Research, BD (company), National League Championship Series, Infusion pump, Timeline of the COVID-19 pandemic in the United States, PCA, Hospital, Risk, Growth, COVID19, Medical device, Pharmaceutical industry

The "Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis 2023-2029 MedSuite Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis 2023-2029 MedSuite Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets" report has been added to ResearchAndMarkets.com's offering.
  • Our complete report suite on the European infusion therapy devices market encompasses six distinct categories: infusion pumps, intravenous (IV) sets, needleless connectors (NLCs), IV filters, stopcocks, and blood transfusion sets.
  • Market Share Insights into Infusion Therapy:
    In the year 2022, B. Braun emerged as the frontrunner in the European infusion therapy device market.
  • Blood Transfusion Set Market - MedCore - The chapter provides an overview of the Blood Transfusion Set market.

AM Best Affirms Credit Ratings of Union Medical Benefits Society Limited

Retrieved on: 
Friday, September 29, 2023
Banking, Professional Services, Insurance, Finance, Communication, AM Best, ALL, Marketing, Unimed, Risk management, Credit, Investment, AM, Growth, News, COVID19

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Union Medical Benefits Society Limited (UniMed) (New Zealand).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Union Medical Benefits Society Limited (UniMed) (New Zealand).
  • AM Best assesses UniMed’s business profile as limited, largely reflecting its small-scale operations and its limited product and geographic diversifications.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

First Cancer Moonshot Award Announced at Yale School of Medicine

Retrieved on: 
Tuesday, September 26, 2023
Emory University, Yale School of Medicine, Georgia Tech, DARPA, University, United States House Committee on Appropriations, Infection, Cancer, Yale Cancer Center, Yale school, Multimedia, Edelson, Lupus, RNA, Cell, Doctor of Philosophy, University of Georgia, ARPA, Messenger, Advanced Research Projects Agency for Health, Patient, Anthony, Immune system, Rosa DeLauro, Yale University, B cell, Virus, COVID19, Vaccine, Health, Dermatology, HAVEN, MD, Medicine

NEW HAVEN, Conn., Sept. 26, 2023 /PRNewswire/ -- Yale School of Medicine and Congresswoman Rosa DeLauro today announced the first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden's Cancer Moonshot program.

Key Points: 
  • NEW HAVEN, Conn., Sept. 26, 2023 /PRNewswire/ -- Yale School of Medicine and Congresswoman Rosa DeLauro today announced the first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden's Cancer Moonshot program.
  • The total award, distributed over three years, will be shared among collaborating teams at Emory University, Yale School of Medicine, and University of Georgia.
  • Richard Edelson , MD, the Anthony N. Brady Professor of Dermatology at Yale School of Medicine, and a former director of Yale Cancer Center, is a co-principal investigator on the project.
  • Edelson added that ARPA-H's crusade to encourage "moonshot" investigative team efforts in cancer is personal to all who have been affected by cancer.

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.